Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study.

Khurram Shahzad Khan Hamish Reed-EmbletonJen LewisPamela BainSajid Mahmud

Published in: Scottish medical journal (2020)

This study contributes to the growing evidence supporting the continued use of ACE inhibitors in COVID-19 disease, although adequately powered randomised controlled trials will be needed to confirm effects.

Keyphrases

angiotensin converting enzyme
coronavirus disease
angiotensin ii
sars cov
metabolic syndrome
insulin resistance
skeletal muscle